Zeto Raises Series A Funding

To Accelerate Commercialization Efforts of its Easy Use Electroencephalography (EEG) Headset and Software Platform

Zeto, Inc. today announced that it has raised $7.3 million in Series A financing led by Seraph Group and joined by Aphelion Capital, SV Tech Ventures and Shangbay Capital.

Zeto raised $4 million previously in dilutive and non-dilutive funding. The new capital will be used to accelerate the commercialization of its lead product, the zEEG headset and software platform, and develop new products to expand its portfolio. zEEG is the first true dry electrode EEG headset to be approved by the U.S. Food and Drug Administration (FDA) for clinical use.

“Since our commercial launch a few months ago, we added several customers who love the product and are utilizing it at high rates. We are glad to validate the strong product-market fit for zEEG. Inspired by the demand, we are excited to expand our commercial team and production capacity to serve our growing customer base,” said Aswin Gunasekar, MS, MBA, Chief Executive Officer and Founder of Zeto. “Our goal is to provide the most seamless and intelligent EEG experience for any clinical need. Current products are far behind what users need and Zeto is building a suite of convenient and intuitive products to eliminate the most time consuming and labor-intensive activities involved in traditional EEG. As a subsequent step, we plan to utilize artificial intelligence to not only supplement the reading physician with analytics and insight but also expand the diagnostic utility of EEG worldwide in areas of medicine where it has been underutilized.”

Zeto’s customer, Wave Neuroscience, Inc., said, “Our extensive intellectual property portfolio and business operations are built on award-winning science and medical innovation. For us to achieve a high level of results we are committed to, we rely on partners that never rest in their quest to achieve the highest standards. Accessing an FDA compliant EEG device that performs at an uncompromising standard, allows for increased throughput and provides a user experience that rivals the latest technology assets, was very attractive to us. Zeto transformed the way we think about EEG capture by advancing technology further in the past two years than the industry had in the prior three or four decades. Zeto provides us the confidence, convenience and data quality that we rely on, day in and day out.”

“We believe a new era is around the corner when researchers can accelerate our understanding of the brain with this breakthrough device and software platform. It not only makes commercial sense but also can serve as the infrastructure and library for neurological knowledge that leads to better diagnosis and treatment of brain disorders,” said Tuff Yen, CEO of Seraph Group, the lead investor.

“We are passionate about brainwaves, consider it a privilege to serve our customers and are committed to bringing great advancements for neurological care,” adds Aswin Gunasekar.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMedâ„¢ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.